Friday, January 19, 2018
Company News: Page (1) of 1 - 09/13/17 Email this story to a friend. email article Print this page (Article printing at page facebook
Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data
- Cosentyx® (secukinumab) is the first and only fully human IL-17A antagonist to show sustained skin clearance rates at 5 years in Phase III in psoriasis(1)- Landmark data show that PASI 90 and PASI 1...
(September 13, 2017)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:USA,Medicine,Disease,healthcare,Therapy,Technology,Surgery,Medication,Vitamins/Nutrition,Womens Health,Physician,Nurse,Health Technologist,Science,Medical Technology,Medical,Other,Medical Professionals,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines